A 48-year-old woman with hypertension (BP 162/105 mmHg) and type 2 diabetes mellitus (HbA1c 8.2%) is seen in the outpatient clinic. She has no history of cardiovascular disease or albuminuria. What is the drug of choice for initiating antihypertensive therapy in this patient?

Explanation

## First-Line Antihypertensive in Hypertension with Diabetes **Key Point:** In patients with hypertension and diabetes mellitus, ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are the preferred first-line agents because they provide renal protection and reduce cardiovascular risk beyond blood pressure lowering alone. **High-Yield:** Ramipril (an ACE inhibitor) is the drug of choice in this case because: 1. **Renal protection:** ACEIs reduce intraglomerular pressure by dilating the efferent arteriole, slowing progression of diabetic nephropathy 2. **Cardiovascular benefit:** ACEIs reduce left ventricular hypertrophy and decrease risk of MI and stroke in diabetic patients 3. **Evidence-based:** MICRO-HOPE trial and multiple guidelines (ADA, ESC/ESH) recommend ACEIs/ARBs as first-line in diabetes 4. **Metabolic neutral:** Unlike thiazides, ACEIs do not worsen glucose control or lipid profile ## Comparison of Options in Diabetic Hypertension | Agent | Class | First-Line in DM? | Rationale | |-------|-------|-------------------|----------| | **Ramipril** | ACE inhibitor | ✓ **Yes** | Renal protection, CV benefit, metabolically neutral, reduces proteinuria | | **Chlorthalidone** | Thiazide diuretic | ✗ No | Worsens glucose control, increases insulin resistance, hyperglycemia risk | | **Diltiazem** | Non-dihydropyridine CCB | ✗ No | No specific renal or cardiac benefit in diabetes; not preferred | | **Labetalol** | Combined alpha/beta-blocker | ✗ No | May mask hypoglycemia symptoms, can worsen glucose control; not first-line | **Clinical Pearl:** - **ACEIs/ARBs are superior** in diabetes because they: - Reduce albuminuria and slow decline in GFR - Decrease left ventricular mass - Reduce cardiovascular events and mortality - **Avoid thiazides and beta-blockers** in diabetes due to metabolic adverse effects - **Dihydropyridine CCBs** (e.g., amlodipine) are acceptable second-line if ACEI/ARB not tolerated **Mnemonic:** **RAAS-I** — **R**enin-**A**ngiotensin-**A**ldosterone **S**ystem **I**nhibitors (ACEIs/ARBs) are **I**deal in diabetes. **Warning:** Do not confuse with uncomplicated essential hypertension — in diabetes, ACEI/ARB is mandatory first-line, not optional. ## Pathophysiology: Why ACEIs Work in Diabetic Nephropathy ```mermaid flowchart TD A[Diabetes mellitus]:::outcome --> B[Hyperglycemia + RAAS activation]:::outcome B --> C[Efferent arteriole vasoconstriction]:::outcome C --> D[Glomerular hyperfiltration]:::outcome D --> E[Proteinuria + GFR decline]:::outcome E --> F[Diabetic nephropathy]:::urgent G[ACE inhibitor / ARB]:::action --> H[Dilate efferent arteriole]:::action H --> I[Reduce intraglomerular pressure]:::action I --> J[Slow GFR decline + reduce proteinuria]:::outcome J --> K[Renal protection]:::outcome ```